Phase I DNA Immunotherapy Trial Initiated in Adults with Breast, Lung, and Pancreatic Cancer
the Cancer Therapy Advisor take:
High levels of hTERT (human telomerase reverse transcriptase) expression are found in 85% of human cancers, and is therefore a significant target for cancer treatment.
Therefore, Inovio Pharmaceuticals recently announced it has initiated a phase I trial of hTERT DNA immunotherapy alone or in combination with an interleukin-12 immune activator (INO-9012; also from Inovio), which will be conducted at the University of Pennsylvania's Abramson Cancer Center.
In a previous study that looked at the activity of the drug in monkeys, who have similar TERT to humans, strong immune responses were observed and showed the potential to destroy cancer cells. The phase I trial is an open-label, dose-escalation study in patients with breast, lung, or pancreatic cancer who are at risk for relapse after surgery or chemotherapy/radiation.
The safety and tolerability of INO-1400 alone or in combination with INO-9012 will be evaluated, with a secondary objective to determine immune responses and evaluate immunotherapy-induced changes. Lung, breast, and pancreatic cancers were selected for this study because they have the first, third, and fourth highest mortality rates, and patients with these diseases often relapse despite surgery and adjuvant therapy.
The hope is that this drug will be yet another weapon in the armament of immunotherapies aimed at empowering the patient’s own immune system to fight their cancer.
High levels of hTERT expression are found in 85% of human cancers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer